European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

Complete remission following pembrolizumab therapy for a patient with nephroureterectomy positive-margin carcinoma in situ and bladder cancer unresponsive to Bacille Calmette–Guérin therapy

“…In the guidelines, adjuvant nivolumab in patients with ypT2 and/or ypN+ disease after neoadjuvant chemotherapy and nephroureterectomy is offered based on the results of CheckMate 274 trial; however, in Japan, pembrolizumab was reported to improve the prognosis of patients with early relapsing disease after the receipt of platinum-based perioperative chemotherapy for highly malignant tumors of the upper urinary tract. [7][8][9] Among intravesical infusion therapy agents, BCG is the only agent associated with a decreased progression risk versus TUR-BT alone. 10 However, despite high initial response rates, up to 50% of patients develop recurrence or become BCG-unresponsive.…”

Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma

“…However, the 2023 EAU guidelines indicate that "Endoscopic ablation should be considered in patients with clinically low-risk cancer." 4 Larger tumors can now also be managed by endoscopy. The 2023 EAU guidelines recommend EM for low-risk UTUC, that is, that <2 cm.…”

Curcumin-loaded graphene oxide quantum dots enhance otoprotective effects via blocking cuproptosis

“…Cisplatin (CIS) has been used in cancer treatment for 40 years ( Bejoy et al, 2022 ; Hyung et al, 2023 ). Although it has side effects and more targeted therapies have recently been introduced, it is still the pillar of cancer treatment ( Peña et al, 2022 ; Rouprêt et al, 2023 ). Unfortunately, two side effects of CIS are ototoxicity and nephrotoxicity ( Bogart et al, 2022 ; Doke et al, 2023 ).…”